Curia Supports Replicate Bioscience’s Phase 1 Clinical Trial of Novel Next-Generation RNA Vaccine

Supply of drug substance manufactured under cGMP supports first-in-human clinical study for RBI-4000 novel self-replicating RNA (srRNA)

ALBANY, N.Y., Sept. 13, 2023 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization, today announced that its partner, Replicate Bioscience, has received IND clearance from the FDA and has dosed the first participant with RBI-4000, a self-replicating (srRNA) rabies vaccine, in a Phase 1 clinical study utilizing clinical material developed as part of the collaboration with Curia.

Curia conducted process development, scale-up and cGMP manufacture of srRNA RBI-4000 drug substance. At approximately 10,000 bases, this srRNA is significantly larger than a conventional linear mRNA and has been historically difficult to manufacture at the scales required for clinical development. Curia’s analytical method development and qualification of the assays were also critical to the release of this srRNA molecule.

“Curia is proud to be a pioneer in manufacturing this new class of srRNA technology by delivering RBI-4000 srRNA drug substance to our partner Replicate in support of their Phase 1 clinical trial,” said Christopher Conway, President, Research & Development, Curia. “We are dedicated to providing advantaged solutions from development to cGMP manufacture for our customers in the mRNA field.”

This new class of srRNA vaccine offers a number of potential improvements to existing mRNA vaccines, including lower dosage requirements and improved tolerability. The advancement also opens the door for further RNA innovation for use in vaccines and therapeutics with fewer constraints on molecule size.

“Our collaboration with Curia helped us manufacture a new class of self-replicating RNAs which have the potential to deliver improved bioactivity, tolerability and efficacy profiles as compared to other RNA technologies,” said Nathaniel Wang, Ph.D., founder and CEO of Replicate. “Curia scaled up a process for longer RNAs that enabled large-scale production at yields, purity and potency to support Replicate’s Phase 1 clinical trial.”

Curia is committed to being a partner of choice from discovery and development through manufacture and commercialization, providing a full suite of services to support small and large molecule, drug substance, drug product aseptic fill-finish and laboratory testing at every phase of the drug development life cycle.

About Curia
Curia, formerly AMRI, is a leading contract research, development, and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s nearly 4,000 employees at 29 locations across the U.S., Europe, and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

Curia Contact Information:
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8920285

Curia soutient l’essai clinique de phase 1 de Replicate Bioscience sur un vaccin novateur à base d’ARN de nouvelle génération

L’entreprise apporte une substance médicamenteuse fabriquée selon les BPFa afin de permettre la première étude clinique chez un être humain du nouvel ARN auto-répliquant (ARNar) RBI-4000

ALBANY, ÉTAT DE NEW YORK, 13 sept. 2023 (GLOBE NEWSWIRE) — Curia, une organisation de recherche, développement et fabrication en sous-traitance de premier plan, a annoncé aujourd’hui que son partenaire, Replicate Bioscience, a reçu une autorisation de sa demande de nouveau médicament expérimental (Investigational New Drug, IND) auprès de la FDA et a dosé le premier participant avec RBI-4000, un vaccin antirabique à base d’ARN auto-répliquant (ARNar) pour une étude clinique de phase 1 employant du matériel clinique développé dans le cadre de sa collaboration avec Curia.

Curia a mené le développement des procédés, la mise à l’échelle et la fabrication respectant les BPFa de la substance médicamenteuse à base d’ARNar RBI-4000. Comptant environ 10 000 bases, cet ARNar est bien plus grand qu’un ARNm linéaire conventionnel et a toujours été difficile à fabriquer aux échelles requises pour le développement clinique. Le développement d’une méthode analytique par Curia et la qualification des essais ont aussi joué un rôle crucial dans le lancement de cette molécule d’ARNar.

« Curia est fière d’être une pionnière dans la fabrication de cette nouvelle classe de technologie d’ARNar en fournissant la substance médicamenteuse à base d’ARNar RBI-4000 à son partenaire Replicate afin de soutenir son essai clinique de phase 1 », a déclaré Christopher Conway, président de la recherche et du développement chez Curia. « Nous nous dédions à offrir des solutions avantageuses, depuis le développement jusqu’à une fabrication respectant les BPFa, à nos clients dans le domaine de l’ARNm. »

Cette nouvelle classe d’ARNar apporte de nombreuses améliorations potentielles aux vaccins existants à base d’ARNm, notamment des posologies plus basses et une meilleure tolérance. Cet avancement ouvre également la voie à une innovation supplémentaire de l’ARN en vue d’une utilisation dans les vaccins et produits thérapeutiques avec moins de contraintes en ce qui concerne la taille des molécules.

« Notre collaboration avec Curia nous a aidés à fabriquer une nouvelle classe d’ARN auto-répliquants qui ont le potentiel d’offrir des profils de bio-activité, de tolérance et d’efficacité améliorés en comparaison avec les autres technologies d’ARN », a commenté Nathaniel Wang, Ph.D., fondateur et PDG de Replicate. « Curia a élaboré un processus pour des ARN plus longs ayant permis une production à grande échelle selon des rendements, une pureté et une puissance à même de soutenir l’essai clinique de phase 1 de Replicate. »

Curia est déterminée à être un partenaire de choix depuis la découverte et le développement jusqu’à la fabrication et la commercialisation, en fournissant une suite complète de services permettant la prise en charge des activités de remplissage-finition aseptique des produits médicamenteux, substances médicamenteuses, petites et grandes molécules, ainsi que des tests en laboratoire, à chaque phase du cycle de vie du développement de médicaments.

À propos de Curia
Curia, anciennement AMRI, est une organisation de recherche, développement et fabrication en sous-traitance de premier plan qui fournit des produits et services allant de la R&D aux clients pharmaceutiques et biopharmaceutiques en passant par la fabrication commerciale. Basés sur 29 sites à travers les États-Unis, l’Europe et l’Asie, les près de 4 000 employés de Curia aident les clients de l’entreprise à passer de la curiosité à la guérison. Pour en savoir plus, rendez-vous sur CuriaGlobal.com.

Contact chez Curia :
Viana Bhagan
+1 518 512 2111
corporatecommunications@CuriaGlobal.com

GlobeNewswire Distribution ID 8921444

Annual Investment Meeting announces new identity as AIM Congress, gears up for 13th edition in Abu Dhabi, May 2024

ABU DHABI, United Arab Emirates, Sept. 13, 2023 (GLOBE NEWSWIRE) — Under its new identity as “AIM Congress,” the Organizing Committee of the World’s Leading Investment Platform will once again gather together regional and international leaders, thinkers, and innovators at the 13th edition of the event taking place from 7 to 9 May 2024 at the Abu Dhabi National Exhibition Centre.

To be anchored on the theme “Adapting to a Shifting Investment Landscape: Harnessing New Potential for Global Economic Development,” AIM Congress 2024 is supported by the Ministry of Industry and Advanced Technology and the Abu Dhabi Department of Economic Development (ADDED) as lead partner.

To be hosted again in the UAE’s vibrant capital, AIM Congress 2024 plans to surpass the success achieved by its last year’s edition which attracted 10,313 participants and 693 speakers from 175 countries.

His Excellency Dr. Thani bin Ahmed Al Zeyoudi, UAE Minister of State for Foreign Trade, expressed his enthusiasm for AIM Congress 2024, stating that, “For more than a decade, AIM Congress has been steadfast in its commitment to promote global economic cooperation and harness the potential of countries especially emerging markets. Amid the backdrop of the shifting global investment scene, it is all-important for countries to adapt and explore new avenues for growth. For its 2024 edition, AIM Congress will continue to be the leading venue where the world’s key economic stakeholders congregate to facilitate dialogue and pave the way for impactful investments that propel a brighter, better future for each and everyone.”

His Excellency Ahmed Jasim Al Zaabi, Chairman of ADDED, said: “Building on the remarkable success of AIM’s previous edition, we are raising the bar to meet the expectations of the global investment community. As the Capital of Capital, Abu Dhabi is leading global conversations on investments outlook and dynamics in an era characterised by mega shifts. Our approach to inward and outward investments is guided by our unwavering commitment to place human development, sustainability, and advanced technology at the core of socio-economic plans at local and international levels, support of ESG agendas, and enhance synergies through international cooperation to improve life for all.”

For his part, Dawood Al Shezawi, President of AIM Global Foundation, commented: “In the face of the various challenges confronting our world today, coupled with the continued decline in global economic growth, emerges the announcement of AIM’s new identity as AIM Congress, which positions itself as a premier venue for investment, providing the optimal platform for esteemed leaders and decision-makers around the world to collectively address our most pressing issues, reshape the global trade and investment landscape, and ultimately foster positive, enduring social and economic impacts in diverse regions worldwide.”

AIM Congress is built upon a foundation of its five key pillars – FDI, FPI, Startups, SMEs, and Future Cities – that underpin the event’s objectives and provide a framework for its activities.

For more details
Shreya Verma – +971 521133926
[email protected]

GlobeNewswire Distribution ID 1000839289

Deriv Group to launch Deriv Prime at IFX EXPO Cyprus 2023

Deriv Prime – Liquidity solution provider

Deriv Prime – Global Liquidity for All

LIMASSOL, Cyprus, Sept. 13, 2023 (GLOBE NEWSWIRE) — Deriv Group has announced that it will launch its institutional arm, Deriv Prime, at the upcoming IFX Expo in Limassol, Cyprus, from the 19th to the 21st of September 2023.

The venture aims to reshape the landscape of liquidity access and trading dynamics by offering comprehensive liquidity solutions to meet the needs of brokerage firms, corporations, startups, and other financial entities, regardless of their business scale.

Deriv Prime marks an advancement in institutional liquidity solutions, presenting a compelling proposition for institutions seeking to navigate the complex trading world. With its cutting-edge technology, extensive network, and institutional-centric approach, Deriv Prime addresses liquidity needs and ushers in a new era of trading possibilities. This disruption could spark a broader trend of reimagining liquidity solutions, ultimately fostering a more dynamic and competitive environment.

Deriv Prime’s ecosystem is underpinned by cutting-edge technology, delivering seamless operations with minimal latency or disruptions. This infrastructure boasts several key features: effortless integration with existing systems, ultra-low latency facilitated by intelligent order routing, reliable access to deep liquidity pools for competitive price feeds, and dedicated support.

“Deriv Prime doesn’t just provide liquidity. It’s a strategic response to the challenges faced by institutions in today’s ever-changing financial landscape,” said Alexandros A. Patsalides, Head of Deriv Prime.

“Deriv Prime accommodates top-of-book liquidity and unparalleled market depth. This adaptability ensures that a broad spectrum of traders can find suitable options within the Deriv Prime ecosystem,” continues Patsalides.

Deriv Prime integration is highlighted for its simplicity, facilitated by FIX protocol that seamlessly links a user’s bridge provider or MT5 gateway. With an average execution speed under 50ms, orders are intelligently routed, ensuring enhanced liquidity and efficiency.

As brokers expand to new markets, portfolio diversification is no longer an option to cater to the needs of different traders. Deriv Prime rises to meet this demand, offering diverse assets that include Forex, Cryptocurrencies, Commodities, Stocks and Indices, and ETFs that can be customised to suit the distinct trading needs of brokers and their clients.

About Deriv

Starting its journey in 1999, Deriv’s mission has been to make online trading accessible to anyone, anywhere. Deriv’s product offering includes intuitive trading platforms, over 200 tradable assets (in markets such as forex, stocks, and cryptocurrencies), unique trade types, and more. With more than 1,200 employees in 20 global offices spread across 16 countries, Deriv strives to provide the best work environment, which includes positive work culture, timely addressing of employee concerns, celebrating achievements, and conducting initiatives to boost their morale.

PRESS CONTACT
Aleksandra Zuzic
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/271135a6-6104-4c25-9256-3f926a0d043b

GlobeNewswire Distribution ID 1000839274

Deriv Group lancera Deriv Prime lors du IFX EXPO Cyprus 2023

Deriv Prime – Les solutions de liquidité

Deriv Prime – des Liquidités mondiales pour tous

LIMASSOL, Chypre, 13 sept. 2023 (GLOBE NEWSWIRE) — Deriv Group a annoncé le lancement prochain de Deriv Prime, sa branche institutionnelle, lors de l’IFX Expo qui se déroulera du 19 au 21 septembre 2023 à Limassol (Chypre).

L’entreprise entend redéfinir le cadre d’accès aux liquidités et la dynamique des transactions, notamment en proposant des solutions de liquidité complètes et adaptées aux besoins des sociétés de courtage, des entreprises, des startups et autres entités financières, quelle que soit la taille de ces dernières.

Deriv Prime marque une avancée en matière de solutions de liquidités institutionnelles, offrant ainsi une proposition convaincante aux institutions qui souhaitent explorer le monde complexe du trading. Grâce à sa technologie de pointe, à son vaste réseau et à son approche axée sur les institutions, Deriv Prime répond aux besoins en matière de liquidité et ouvre la voie à une nouvelle ère de perspectives en matière de trading. Ce changement pourrait conduire à une plus grande tendance visant à repenser les solutions de liquidités et à favoriser, à terme, un environnement plus dynamique et plus concurrentiel.

L’écosystème de Deriv Prime est soutenu par une technologie de pointe, ce qui favorise un fonctionnement continu avec une latence et des perturbations minimales. On peut citer entre autres principales fonctionnalités de cette infrastructure : une intégration simple aux systèmes existants, une latence ultra-faible facilitée par un routage des ordres, un accès fiable à d’importants pools de liquidité pour des cours concurrentiels et une assistance dédiée.

D’après le responsable de Deriv Prime, Alexandros A. Patsalides, « Deriv Prime est non seulement une solution de liquidités, mais il s’agit également d’une réponse stratégique aux défis auxquels font face les institutions dans le secteur financier actuel toujours plus dynamique.

« Deriv Prime offre une liquidité haut de gamme et une profondeur de marché unique. Une telle adaptabilité permet à un large spectre de traders de trouver des options appropriées à l’intérieur de l’écosystème Deriv Prime » poursuit-il.

L’intégration de Deriv Prime se distingue par sa simplicité, facilitée par le protocole FIX qui relie parfaitement le fournisseur de pont ou la passerelle MT5 d’un utilisateur. Les ordres sont acheminés de manière intelligente, avec une vitesse d’exécution moyenne inférieure à 50 ms, ce qui garantit une liquidité et une efficacité accrues.

À mesure que les brokers s’ouvrent à de nouveaux marchés, la diversification du portefeuille n’est plus une option adaptée aux besoins des différents traders. Deriv Prime répond à cette demande grâce à une offre d’actifs, notamment le Forex, les cryptomonnaies, les matières premières, les actions et indices, ainsi que des ETF qui sont personnalisables et adaptables aux différents besoins de trading des brokers et de leurs clients.

À propos de Deriv

Deriv a commencé son périple en 1999. Depuis lors, sa mission a consisté à rendre le trading en ligne accessible à tous et partout. Les produits de Deriv comprennent des plateformes de trading intuitives, plus de 200 actifs à trader (sur des marchés comme celui des devises, des actions et des cryptomonnaies), des types de transactions uniques, etc. Deriv déploie tous les efforts pour créer les meilleures conditions de travail pour ses plus de 1 200 employés répartis dans 20 bureaux de 16 pays du monde, notamment grâce à une culture de travail positive, la résolution rapide des préoccupations des employés, la célébration des réalisations et la mise en œuvre d’initiaves de motivation du personnel.

CONTACT PRESSE
Aleksandra Zuzic
[email protected]

Une photo accompagnant ce communiqué de presse est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/271135a6-6104-4c25-9256-3f926a0d043b

GlobeNewswire Distribution ID 1000839274

O Grupo Deriv vai lançar a Deriv Prime na IFX EXPO Cyprus 2023

Deriv Prime – Provedor de soluções de liquidez

Deriv Prime – Liquidez global para todos

LIMASSOL, Chipre, Sept. 13, 2023 (GLOBE NEWSWIRE) — Deriv Group anunciou que irá lançar a sua divisão institucional, Deriv Prime, na próxima IFX Expo em Limassol, Chipre, de 19 a 21 de setembro de 2023.

O empreendimento visa remodelar o panorama de acesso à liquidez e dinâmica de negociação ao oferecer soluções de liquidez abrangentes para atender às necessidades de corretoras, empresas, startups e outras entidades financeiras, independentemente do tamanho de seus negócios.

A Deriv Prime marca um avanço nas soluções de liquidez institucional, apresentando uma proposta atraente para as instituições que procuram navegar no complexo mundo do trading. Com a sua tecnologia de ponta, extensa rede e abordagem centrada nas instituições, a Deriv Prime responde às necessidades de liquidez e inaugura uma nova era de possibilidades de negociação. Esta disrupção poderá desencadear uma tendência mais alargada de reformulação das soluções de liquidez, promovendo um ambiente mais dinâmico e competitivo.

O ecossistema da Deriv Prime é sustentado por uma tecnologia de ponta, oferecendo operações contínuas com mínima latência ou interrupções. Essa infraestrutura apresenta diversas características essenciais: integração sem esforço com sistemas existentes, latência ultra-baixa facilitada por roteamento inteligente de pedidos, acesso confiável a pools de liquidez profunda para feeds de preços competitivos e suporte dedicado.

“A Deriv Prime não se limita a fornecer liquidez. Trata-se de uma resposta estratégica aos desafios enfrentados pelas instituições no atual panorama financeiro em constante mutação”, afirmou Alexandros A. Patsalides, Diretor da Deriv Prime.

“A Deriv Prime acomoda liquidez de topo de gama e uma profundidade de mercado incomparável. Essa adaptabilidade garante que um amplo espectro de traders possa encontrar opções adequadas dentro do ecossistema da Deriv Prime,” continua Patsalides.

A integração da Deriv Prime é destacada pela sua simplicidade, facilitada pelo protocolo FIX, que vincula perfeitamente o provedor de bridge ou o gateway MT5 do usuário. Com uma velocidade média de execução inferior a 50 ms, as ordens são encaminhadas de forma inteligente, garantindo maior liquidez e eficiência.

À medida que as corretoras se expandem para novos mercados, a diversificação da carteira deixa de ser uma opção para satisfazer as necessidades de diferentes corretoras. A Deriv Prime surge para atender a essa procura, oferecendo diversos ativos que incluem Forex, Criptomoedas, Matérias-primas, Ações e Índices, e ETFs que podem ser personalizados para atender às necessidades de negociação específicas das corretoras e dos seus clientes.

Sobre a Deriv

Tendo iniciado o seu percurso em 1999, a missão da Deriv tem sido tornar a negociação online acessível a qualquer pessoa, em qualquer lugar. A oferta de produtos da Deriv inclui plataformas de negociação intuitivas, mais de 200 ativos negociáveis (em mercados como forex, ações e criptomoedas), tipos de negociação exclusivos e muito mais. Com mais de 1.200 funcionários em 20 escritórios globais espalhados por 16 países, a Deriv esforça-se por proporcionar o melhor ambiente de trabalho, o que inclui uma cultura de trabalho positiva, a resolução atempada das preocupações dos funcionários, a celebração de conquistas e a realização de iniciativas para aumentar o seu moral.

CONTATO DE IMPRENSA
Aleksandra Zuzic
[email protected]

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/271135a6-6104-4c25-9256-3f926a0d043b

GlobeNewswire Distribution ID 1000839274